NEXGEL, Inc. Provides Preliminary Revenue Guidance for the Second, Third and Fourth Quarter of 2024
July 08, 2024 at 04:05 pm EDT
Share
NEXGEL, Inc. provided preliminary revenue guidance for the second, third and fourth quarter of 2024. Based on preliminary and unaudited review, the Company anticipates Second Quarter 2024 Revenue to be $1.4 million, an increase of approximately 20% year-over-year and 10% sequentially.
The Company anticipates Third Quarter 2024 Revenue to be $2.2 million, an increase of 83% year-over-year.
The Company anticipates Fourth Quarter 2024 Revenue to be $2.6 million, an increase of 140% year-over-year.
NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including ultra-gentle, high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CG labs segment comprises the CG Converting and Packaging, LLC used for the Companyâs converting and packaging business, which is based in Granbury, Texas. Its hydrogel consumer products are marketed under the brand names MedaGel and LumaGel Beauty. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Dermablock. It also specializes in eye and eyelash consumer products.
NEXGEL, INC. 
